Pharmaceutical Technology
MAY 25, 2023
The Medicines and Healthcare products Regulatory Agency (MHRA) aims to launch a pilot genetic biobank that will gather patient data to associate drug-related adverse events to their genetic makeup. The Yellow Card biobank will launch as a joint venture with the UK-government funded entity Genomics England on June 1.
Cloudbyz
NOVEMBER 5, 2021
The short answer is that all Biobanks are Biorepositories, but not all Biorepositories are Biobanks. Realistically speaking, the terms “Biobank” and “Biorepository” are used pretty interchangeably. The differences we can point out when someone asks: What is the difference between Biobanks and Biorepositories?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
BioTech 365
AUGUST 17, 2021
Epigenomics AG / Key word(s): Strategic Company Decision/Change in Forecast Epigenomics AG: Execution of a Biobank Sale Agreement and Update of Guidance 17-Aug-2021 / 21:00 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) … Continue reading →
XTalks
FEBRUARY 4, 2021
Biobanks are used for the coordination of high-yield patient sample collection. Moreover, biobanks are no longer passive biorepositories for accrual of samples and serve a more utilitarian function in identifying and coordinating specific research cohorts for longitudinal and prospective studies. Biobanking Models.
Cloudbyz
NOVEMBER 3, 2021
Automated Biobanking. Automated Biobanking is an approach to radically reduce the manual tasks involved in properly storing, labeling, authenticating, and monitoring samples, as well as increasing the ease of displaying much of their data values and making sample retrieval easier. Cost Recovery Fees for Biobanks.
pharmaphorum
NOVEMBER 24, 2022
More than two years on, the EU medicines regulator has now selected the first set of data partners to collaborate with DARWIN EU, which focuses on real-world evidence collected on a patient’s health status or delivery of healthcare from a variety of sources, other than conventional clinical trials.
Trialfacts
SEPTEMBER 12, 2024
Their work is driven by a profound understanding of disease biology and supported by advanced discovery platforms such as genetics and genomics, gene editing, bioinformatics, proteomics, bioengineering, image analysis, biobanks, disease-specific stem cell lines, and various animal models.
Expert insights. Personalized for you.
130 
Let's personalize your content